Damora Therapeutics, Inc. (DMRA) earnings date
Mar 9, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 3 releases on file; at least 4 are needed |
Last 3 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q4 FY2025 | Tue, Mar 10, 2026 | before open | 69 | 8-K |
| Q3 FY2022 | Fri, Jan 6, 2023 | before open | 98 | 8-K |
| Q3 FY2020 | Tue, Jan 5, 2021 | after close | 97 | 8-K |
What they guided beta
| Q4 FY2025 | "Exhibit 99.1 Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders -- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with two clinical proof-of-concept datasets expected mid-2027 -- -- Strong financial position with approximately $535 million of cash and cash equivalents as of February 28, 2026, with anticipated runway into Phase 3 development of DMR-001" exhibit |
| Q4 FY2025 | "With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes." exhibit |
| Q3 FY2022 | "INNOVATIVE PLATFORMS TARGETING CORE DISEASE PROCESSES Pioneers in galectin-3 and LOXL2 based pharmacology First-in-class oral small-molecule, target specific inhibitors ADDRESSING DISEASE AREAS WITH SIGNIFICANT UNMET MEDICAL NEED All programs address: Diseases characterized by clear unmet medical need Multi-billion-dollar market opportunities ADVANCING BROAD PIPELINE IN FIBROTIC DISEASE Four Phase 2 programs: Non-small cell lung cancer (NSCLC) Idiopathic pulmonary fibrosis (IPF)* Myelofibrosis (MF) Liver cirrhosis** PROOF OF CONCEPT ALREADY ESTABLISHED FOR BOTH APPROACHES Galectin-3 Inhibito" exhibit |
| Q3 FY2022 | "Galecto oncology opportunities Inhibition of galectin-3 may have anti-tumor activity as monotherapy and in combination with CPIs, chemo- and radiotherapy Galectin-3 plays central role for the hallmarks of cancer and is linked to poor survival for many solid tumors Galectin-3 is a negative regulator of immune cell functions and drives low CPI response rate GB1211 is a specific oral galectin-3 inhibitor ready for Phase 2 Anti-tumor effects in preclinical models Well-tolerated and no observed adverse safety or drug interaction signals Galecto collaborating with Roche on upcoming NSCLC first line " exhibit |
| Q3 FY2022 | "INNOVATIVE PLATFORMS TARGETING CORE DISEASE PROCESSES Pioneers in galectin-3 and LOXL2 based pharmacology First-in-class oral small-molecule, target specific inhibitors ADDRESSING DISEASE AREAS WITH SIGNIFICANT UNMET MEDICAL NEED All programs address: Diseases characterized by clear unmet medical need Multi-billion-dollar market opportunities ADVANCING BROAD PIPELINE IN FIBROTIC DISEASE Four Phase 2 programs: Non-small cell lung cancer (NSCLC) Idiopathic pulmonary fibrosis (IPF)* Myelofibrosis (MF) Liver cirrhosis** PROOF OF CONCEPT ALREADY ESTABLISHED FOR BOTH APPROACHES Galectin-3 Inhibito" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/DMRA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/DMRA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/DMRA/"><img src="https://veritasdata.dev/embed/DMRA.svg" alt="DMRA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/DMRA/)
Script
<script async src="https://veritasdata.dev/embed/DMRA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/DMRA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.